Telix Pharmaceuticals Ltd (TLX.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Cash Flows From Operating Activities | |||||
| Operating Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Investing Activities | |||||
| Purchase Sale Intangibles | N/A | -4,694 | N/A | N/A | -4 |
| Other Investing Activity | -1,112 | -1,461 | -1,790 | -747 | -80 |
| Investing Cash Flow | $-1,112 | $-6,155 | $-1,790 | $-747 | $-85 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 353 | N/A | N/A | N/A | N/A |
| Debt Repayment | N/A | -1 | -7 | -56 | -8 |
| Common Stock Issued | 71 | 736 | 133,825 | N/A | 2,043 |
| Other Financing Activity | -287 | -173 | -6,643 | -116 | -230 |
| Financing Cash Flow | $137 | $561 | $127,175 | $-172 | $1,805 |
| Exchange Rate Effect | 883 | 1,247 | -671 | -1,142 | 1,216 |
| Beginning Cash Position | 79,806 | 106,443 | 16,526 | 33,239 | 35,604 |
| End Cash Position | 76,232 | 84,343 | 116,035 | 15,975 | 32,903 |
| Net Cash Flow | $-4,457 | $-23,347 | $100,181 | $-16,122 | $-3,917 |
| Free Cash Flow | |||||
| Capital Expenditure | N/A | -4,694 | N/A | N/A | -4 |
| Free Cash Flow | 0 | -4,694 | 0 | 0 | -4 |